Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Electrophile-First Screening Identifies Covalent Aminothiazole Scaffold Inhibitors for Ubiquitin-Conjugating Enzyme UBE2D2.

Created on 12 Nov 2026

Authors

Siying Liu, Tao Zheng, Xinyu Wu, Huiling Wang, Shuaishuai Ni, Yilin Dou, Boyi Li, Lu Wang, Yunyuan Huang, Xin Chen, Jinrong Min

Published in

Journal of medicinal chemistry. Volume 69. Issue 21. Pages 25914-25929. Nov 12, 2026.

Abstract

UBE2 family of E2 ubiquitin-conjugating enzymes occupy central positions in multiple ubiquitination pathways and have been implicated in cancers, motivating efforts to develop chemical probes to interrogate their functions. In this study, we identified XY54 as a covalent modifier of UBE2D2 that engages both C85 and C111 by using an electrophile-first screening approach coupled with X-ray crystallography. Structure-guided structure-activity relationship optimization of XY54 yielded XY54-24, in which modifications of the amide and ester groups of XY54 selectively abolished its binding to C111 while enhancing affinity for C85. XY54-24 inhibited UBE2D2 enzymatic activity in vitro and suppressed the proliferation of A549 lung cancer cells. Collectively, this study identifies covalent aminothiazole scaffold inhibitors for targeting UBE2D2 and provides a structural foundation for further development of selective UBE2D2 chemical probes.

PMID:
43018603
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement